Zulresso Uses Side Effects Dosages Interactions
Zulresso is the first drug approved by the Food and Drug Administration (FDA) to treat postpartum depression (PPD). Experts believe that Zulresso (also known by its generic name, brexanolone) improves the symptoms of PPD by interacting with gamma-aminobutyric acid (GABA), a neurotransmitter. In two clinical trials, Zulresso improved symptoms of postpartum depression significantly and rapidly, and its effects lasted for at least 30 days after treatment. Zulresso is an injectable medication given intravenously (IV) by a healthcare provider in a certified health facility....